Pharmaceutical

Celltrion USA seeks FDA approval for CT-P47 biosimilar

Celltrion USA has filed a biologics licence application (BLA) with the US FDA for its biosimilar candidate CT-P47.

Jan 29, 2024 - 18:00
Celltrion USA seeks FDA approval for CT-P47 biosimilar
Celltrion USA has filed a biologics licence application (BLA) with the US FDA for its biosimilar candidate CT-P47.
Read the original article

Tags:

Previous Article

FDA grants priority review for Daiichi Sankyo-AstraZeneca’s Enhertu

Next Article

Bristol Myers Squibb’s Abecma recommended for EU approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CMN-005 by CoImmune for Follicular Lymphoma: Likelihood...

Sep 10, 2024

AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery

AION Labs and BioMed X launch sixth challenge for AI-dr...

May 30, 2023

STAT+: Sickle cell gene therapies could be cost-effective even if priced as high as $1.9 million

STAT+: Sickle cell gene therapies could be cost-effecti...

Apr 13, 2023